Larvol Delta - Phase-2-Findings-Show-Wugens-Investigational-Allogeneic-CART-WUCART007-Was-Highly-Effective-and-Surpassed-Standard-of-Care-in-Treating-HardtoTreat-TALLLBL-Data-Presented-Today-at-European-Hematology-Association-EHA-2024-Hybrid-Congress

WU CART 007 - Wugen

https://www.globenewswire.com/news-release/2024/06/14/2898923/0/en/Phase-2-Findings-Show-Wugen-s-Investigational-Allogeneic-CAR-T-WU-CART-007-Was-Highly-Effective-and-Surpassed-Standard-of-Care-in-Treating-Hard-to-Treat-T-ALL-LBL-Data-Presented-To.html

Jun 14, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next